Clarity Pharmaceuticals utilises their unique radiopharmaceutical products with the latest PET imaging technology to track the path of biopharmaceuticals inside the body. The value of this is that more targeted drugs can potentially be developed that reach the diseased cells specifically, without affecting surrounding healthy cells. With funding from Commercialisation Australia, Clarity Pharmaceuticals will obtain expert regulatory advice and undertake an imaging validation study to expand its PET imaging service, which is currently limited to animal studies, to include human clinical trials.